Skip to main content

Table 1 Participant characteristics by country

From: The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus

Variables Australia n = 20 Brazil n = 20 France n = 30 Total N = 70
Demographic factors
 Male Sex 17 (85.0) 6 (30.0) 21 (70.0) 44 (62.9)
 Age 48.7 (6.0) 51.8 (9.4) 50.45 (9.7) 50.3 (8.5)
 Weight (kg) 83.0 (19.9) 66.8 (15.4) 70.5 (13.4) 73.0 (17.1)
 Married/partner 5 (25.0) 11 (55.0) 17 (56.7) 33 (47.1)
 Ethnicity Caucasian 18 (90.0) 12 (60.0) 23 (82.1) 53 (75.7)
 Living alone 7 (35.0) 2 (10.0) 9 (30.0) 18 (25.7)
 Living with children 4 (20) 10 (50.0) 14 (46.6) 25 (35.7)
 Education ≥ university 3 (15.0) 4 (20.0) 7 (23.3) 14 (20.0)
 Employmenta 12 (60.0) 6 (30.0) 20 (68.9) 48 (69.6)
 Current smoker 12 (60.0) 7 (35.0) 15 (50.0) 34 (48.6)
 Alcohol last month 15 (75.0) 5 (25.0) 13 (44.8) 33 (47.8)
 Past history of Injecting drugs 17 (85.0) 3 (15.8) 14 (48.3) 34 (50.0)
Treatmentb
 Past history 5 (26.3) 2 (10.0) 17 (58.6) 24 (35.3)
 Current 14 (70.0) 15 (75.0) 13c (46.4) 42 (61.8)
 Pill burden (total number) 8.1 (6.3) 8.2 (4.8) 9.0 (5.4) 8.5 (5.4)
 Antidepressant drugs 7 (35.0) 12 (60.0) 5 (16.7) 24 (34.3)
 Antianxiety drugs 5 (20.0) 4 (20.0) 4 (13.3) 13 (18.6)
 Sedative drugs 4 (20.0) 0 (0.0) 5 (17.9) 9 (13.4)
Clinical factors
 Time since diagnosis (years) 5.0 (13.8) 3.5 (4.5) 8.0 (10.3) 5.0 (10.0)
 HIV-Coinfection 5 (29.4) 5 (27.8) 4 (26.8) 14 (28.0)
 Depression, self-reported (past month) 11 (55.0) 10 (50.0) 12 (41.4) 33 (47.8)
 Symptoms (total number) 12.0 (7.0) 15.0 (13.5) 12.5 (6.0) 13.0 (7.0)
  1. aInclusive of full time and part time work; bBoth interferon alpha and pegylated in combination with ribavirin; c8 patients (32 %) receiving directly acting antiviral drugs
  2. Data are summarised as count (percentage) for categorical variables, and mean (SD) for numerical variables